WGS
GeneDx Holdings Corp.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
GeneDx Holdings Corp.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+4.48%
vs ±18.8% implied · ×0.24
shaded = implied · ▲▼ = realized
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
No thesis.
Annual filing, covered
10-K parsed · Feb 23 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 23 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
GeneDx Holdings Corp.
69.14
−1.88 · −2.65%
post 68.09 −1.52%
Same SIC code · 6
Same SEC industry code: Privia Health Group, Inc., LifeStance Health Group, Inc., Pennant Group, Inc. and 3 more; of GeneDx Holdings Corp.'s 6 closest co-movers, 1 shares that code.
Same SIC code · 6
Same SEC industry code: Privia Health Group, Inc., LifeStance Health Group, Inc., Pennant Group, Inc. and 3 more; of GeneDx Holdings Corp.'s 6 closest co-movers, 1 shares that code.
Linked news
Expected move
Inputs8Q avg ±21.4%·×0.47·cheap
spot 69.06exp Nov 6ATM strike 69ATM straddle 8.23IV 108%
| Manager | Value | % base | |
|---|---|---|---|
| Corvex | $328.5M | 14.63% | +48.21% |
| Casdin Capital | $254.5M | 11.33% | +23.28% |
| BlackRockindex-like | $117.1M | 5.22% | +10.03% |
| Goldman Sachs | $114.6M | 5.10% | +25.05% |
| ARK | $110.5M | 4.92% | +21.56% |
| Manager | Value | % base | |
|---|---|---|---|
| Corvex | $328.5M | 14.63% | +48.21% |
| Casdin Capital | $254.5M | 11.33% | +23.28% |
| BlackRockindex-like | $117.1M | 5.22% | +10.03% |
| Goldman Sachs | $114.6M | 5.10% | +25.05% |
| ARK | $110.5M | 4.92% | +21.56% |
Bull3
Bear2